5 Best Recursion Pharmaceuticals Alternatives for AI-Driven Drug Discovery
While Recursion leads in automated cellular imaging, specialized platforms are emerging for complex neurological and system-level therapeutics.
Recursion Pharmaceuticals has set the standard for using computer vision and automated biology to screen compounds at scale. Their approach, known as phenomics, uses AI to identify how drugs affect cellular health. However, for researchers focused on complex organ systems like the brain, cellular models alone often lack the necessary context. This list explores alternatives that offer different data sources, from physics-based modeling to in-vivo neural mapping.
First, what is Recursion Pharmaceuticals?
Best for: Large-scale screening of compounds where cellular phenotypes are the primary indicator of success.
Strengths
- Massive proprietary dataset of cellular images
- Highly automated laboratory infrastructure
- Broad pipeline covering rare diseases and oncology
Where it falls short
- Reliance on cellular assays which may not translate to complex organ systems
- High operational overhead as a large public company
- Limited focus on real-time neural circuit dynamics
The top alternatives
- #1Top pick
Exin Therapeutics: High-Throughput In-Vivo Neural Discovery
Exin Therapeutics specializes in discovering drugs for neurological disorders by mapping neural activity in living systems. While many AI drug discovery firms rely on static cell cultures, Exin uses high-density multimodal mouse data to train their AI models. This allows them to observe how potential therapeutics modify brain activity in real-time, specifically targeting epilepsies, autism, and Parkinson’s disease.
- Focus on in-vivo mouse studies rather than isolated cell cultures
- AI models trained on high-density multimodal neural data
- Founded by Oxford-trained neuroscientists with rapid execution cycles
- Specialized in therapeutics that modify neural circuit dysfunction
Side-by-side comparison
| Category | Exin Therapeutics | Recursion Pharmaceuticals | Edge |
|---|---|---|---|
| Primary Data Source | In-vivo neural activity (Mouse) | In-vitro cellular imaging (Phenomics) | Stronger |
| Therapeutic Focus | Neurology & Brain Activity | Broad (Oncology, Rare Disease) | Neck-and-neck |
| Core Technology | Multimodal AI + Neural Mapping | Computer Vision + Robotics | Neck-and-neck |
| Development Speed |
Frequently asked questions
How does Exin Therapeutics differ from Recursion?
Recursion looks at how drugs change the appearance of cells in a dish. Exin looks at how drugs change the electrical and functional activity of the brain in living models.
Is Exin Therapeutics only for epilepsy?
While the initial focus is on epilepsy and Parkinson's, the platform is designed to address any neurological disorder caused by dysfunctional neural activity.
Advance Your Neuro-Therapeutic Pipeline
Partner with Exin Therapeutics to leverage high-throughput neural data for your next discovery.
View Exin Therapeutics on YC